%0 Journal Article
%T Multi-stakeholder consensus on a target product profile for an HIV cure.
%A Lewin SR
%A Attoye T
%A Bansbach C
%A Doehle B
%A Dubé K
%A Dybul M
%A SenGupta D
%A Jiang A
%A Johnston R
%A Lamplough R
%A McCune JM
%A Nabel GJ
%A Ndung'u T
%A Pottage J
%A Ripin D
%A Rooney JF
%A Sikazwe I
%A Nsubuga M
%A Warren M
%A Deeks SG
%A  
%J Lancet HIV
%V 8
%N 1
%D 01 2021
%M 33271125
%F 16.07
%R 10.1016/S2352-3018(20)30234-4
%X Developing a cure for HIV is a global priority. Target product profiles are a tool commonly used throughout the drug development process to align interested parties around a clear set of goals or requirements for a potential product. Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy. An intervention that successfully cured a reasonable fraction of adults would be sufficient to advance to the clinic. These target product profiles will require further discussion and ongoing revisions as the field matures.